Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours

Navoximod (GDC-0919) is a small molecule inhibitor of indoleamine-2,3-dioxygenase 1. This study investigated the safety, tolerability and pharmacokinetics of navoximod alone and in combination with atezolizumab in Japanese patients with advanced solid tumours. This was a phase I, open-label, dose-es...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebata, Takahiro, Shimizu, Toshio, Fujiwara, Yutaka, Tamura, Kenji, Kondo, Shunsuke, Iwasa, Satoru, Yonemori, Kan, Shimomura, Akihiko, Kitano, Shigehisa, Koyama, Takafumi, Sato, Natsuko, Nakai, Kiyohiko, Inatani, Michiyasu, Yamamoto, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066107/
https://www.ncbi.nlm.nih.gov/pubmed/31124055
http://dx.doi.org/10.1007/s10637-019-00787-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066107/
https://www.ncbi.nlm.nih.gov/pubmed/31124055
http://dx.doi.org/10.1007/s10637-019-00787-3

Ejemplares similares